Ontology highlight
ABSTRACT:
SUBMITTER: Ackler S
PROVIDER: S-EPMC4618648 | biostudies-other | 2015 Oct
REPOSITORIES: biostudies-other
Pharmacology research & perspectives 20150901 5
The Bcl-2 family inhibitors venetoclax and navitoclax demonstrated potent antitumor activity in chronic lymphocytic leukemia patients, notably in reducing marrow load and adenopathy. Subsequent trials with venetoclax have been initiated in non-Hodgkin's lymphoma and multiple myeloma patients. Traditional preclinical models fall short either in faithfully recapitulating disease progression within such compartments or in allowing the direct longitudinal analysis of systemic disease. We show that i ...[more]